These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22796437)

  • 1. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
    Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
    Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
    Kirabo A; Embury J; Kiss R; Polgár T; Gali M; Majumder A; Bisht KS; Cogle CR; Keseru GM; Sayeski PP
    J Biol Chem; 2011 Feb; 286(6):4280-91. PubMed ID: 21127060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
    Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
    Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
    Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
    J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders.
    Hsieh PP; Olsen RJ; O'Malley DP; Konoplev SN; Hussong JW; Dunphy CH; Perkins SL; Cheng L; Lin P; Chang CC
    Mod Pathol; 2007 Sep; 20(9):929-35. PubMed ID: 17643100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
    Tiedt R; Hao-Shen H; Sobas MA; Looser R; Dirnhofer S; Schwaller J; Skoda RC
    Blood; 2008 Apr; 111(8):3931-40. PubMed ID: 18160670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
    Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
    Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
    Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
    Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
    Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
    FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.
    Lacout C; Pisani DF; Tulliez M; Gachelin FM; Vainchenker W; Villeval JL
    Blood; 2006 Sep; 108(5):1652-60. PubMed ID: 16670266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.
    Wernig G; Kharas MG; Mullally A; Leeman DS; Okabe R; George T; Clary DO; Gilliland DG
    Leukemia; 2012 Apr; 26(4):720-7. PubMed ID: 22005786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
    Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
    Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
    Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
    PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.